Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Bilal A SiddiquiBrian F ChapinSonali JindalFei DuanSreyashi BasuShalini S YadavAi-Di GuAlexsandra B EspejoMichelle KinderCurtis A PettawayJohn F WardRebecca S Slack TidwellPatricia TroncosoPaul G CornChristopher J LogothetisRoland KnoblauchNatalie HutnickMarco GottardisCharles G DrakePadmanee SharmaSumit K SubudhiPublished in: Journal for immunotherapy of cancer (2023)
immune cells were not consistently observed with edicotinib. Neither myeloid-targeted agent alone was sufficient to generate antitumor responses in prostate cancer; thus, combinations with agents to induce T cell infiltration (eg, ICTs) will be needed to overcome the immunosuppressive prostate TME.